Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab combinations in less fit patients with chronic lymphocytic leukemia
ISRCTN09988575Phase 3Completed
- Sponsor
- Royal Brompton and Harefield hospitals
- Start
- Dec 2011
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Ofatumumab + chlorambucil with Ofatumumab + bendamustine (2 arms). Primary endpoint: Progression-free survival. Started Dec 2011; status: completed.
02
Drugs
ofatumumabchlorambucilbendamustine
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ISRCTN09988575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN09988575.